Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Jun
17
Today In Oncology
Neoadjuvant Sacituzumab Govitecan in MIBC
Thyroid Cancer Reproductive Lifespan, Hormone Therapy Potentially Linked to Incidence
Two-Pronged Nudges Result in Timely Conversations Around Priorities of Cancer Care
MIBC Intravesical Recombinant BCG and Chemoimmunotherapy
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo